Relugolix was superior to the injectable luteinizing hormone–releasing hormone agonist leuprolide in providing sustained suppression of testosterone.
Adjuvant chemotherapy was associated with improved overall survival for patients with recurrence scores of 26 or higher.
Adding atezolizumab to platinum-based chemotherapy significantly prolonged progression-free survival.
Most patients had durable response and improved clinical benefit in a phase II study.
Thrombosis is prevalent in sickle cell patients, especially following hospital discharge and in the presence of vascular access, and is potentially influenced by thrombomodulin gene mutations.
Survival was significantly prolonged with combination therapy versus conventional therapy with sorafenib.
Progression-free survival was longer with olaparib than with abiraterone or enzalutamide in patients with BRCA1, BRCA2, or ATM alterations.
Increasing the frequency of low-dose aspirin dosing improved platelet inhibition.
Our approach to considering non–peer-reviewed studies during the COVID-19 pandemic
Among previously treated patients with FGFR2 fusions or rearrangements, 36% achieved an objective response.
Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.
Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.
Progression-free survival was prolonged with front-line brigatinib versus crizotinib.
Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.
Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.
Two-year overall survival was significantly improved with durvalumab versus placebo.
Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.
Progression-free survival was significantly longer with olaparib than with placebo.
Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.
Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.